These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 19894306)

  • 1. [Multiple sclerosis at the time of world-wide use of disease modifying treatment].
    Gusev EI; Boĭko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7 Suppl 2):4-9. PubMed ID: 19894306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mode of action and clinical studies with fumarates in multiple sclerosis.
    Salmen A; Gold R
    Exp Neurol; 2014 Dec; 262 Pt A():52-6. PubMed ID: 24568735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B; Hartung HP
    Ann Neurol; 2007 Oct; 62(4):314-26. PubMed ID: 17969020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to disease-modifying drugs in patients with multiple sclerosis: a consensus statement from the Middle East MS Advisory Group.
    Yamout BI; Dahdaleh M; Al Jumah MA; Al-Shammri S; Al Sharoqi I; Al-Tahan AR; Bohlega S; Deleu D; Inshasi J; Khalifa A; Szólics M
    Int J Neurosci; 2010 Apr; 120(4):273-9. PubMed ID: 20374075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approaches to neuroprotective strategies in multiple sclerosis.
    Tselis A; Khan OA; Lisak RP
    Expert Opin Pharmacother; 2010 Dec; 11(17):2869-78. PubMed ID: 20687779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.
    Twork S; Nippert I; Scherer P; Haas J; Pöhlau D; Kugler J
    Curr Med Res Opin; 2007 Jun; 23(6):1209-15. PubMed ID: 17559722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pathogenetic treatment of multiple sclerosis: the present and the future].
    Boĭko AN; Stoliarov ID; Sidorenko TV; Kulakova OV; Kol'iak EV; Petrov AM; Il'ves AG; Nikiforova IG; Favorova OO; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7 Suppl 2):90-9. PubMed ID: 19894313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balancing Early Aggression Against Risk of Progression in Multiple Sclerosis.
    Duquette P; Giacomini PS; Bhan V; Hohol M; Schecter R
    Can J Neurol Sci; 2016 Jan; 43(1):33-43. PubMed ID: 26611431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-modifying treatments for progressive multiple sclerosis.
    Comi G
    Mult Scler; 2013 Oct; 19(11):1428-36. PubMed ID: 24062415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.
    Tan H; Cai Q; Agarwal S; Stephenson JJ; Kamat S
    Adv Ther; 2011 Jan; 28(1):51-61. PubMed ID: 21153000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New therapeutic approaches for multiple sclerosis.
    De Jager PL; Hafler DA
    Annu Rev Med; 2007; 58():417-32. PubMed ID: 17217332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the Treatment of Multiple Sclerosis.
    Goldschmidt C; McGinley MP
    Neurol Clin; 2021 Feb; 39(1):21-33. PubMed ID: 33223085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple sclerosis: new insights in pathogenesis and novel therapeutics.
    Ontaneda D; Hyland M; Cohen JA
    Annu Rev Med; 2012; 63():389-404. PubMed ID: 21888515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of statins in the treatment of multiple sclerosis.
    Ciurleo R; Bramanti P; Marino S
    Pharmacol Res; 2014 Sep; 87():133-43. PubMed ID: 24657241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of multiple sclerosis: have available therapies impacted long-term prognosis?
    Trojano M; Paolicelli D; Tortorella C; Iaffaldano P; Lucchese G; Di Renzo V; D'Onghia M
    Neurol Clin; 2011 May; 29(2):309-21. PubMed ID: 21439443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adherence to long-term therapy with disease modifying drugs].
    Sidorenko TV; Boĭko AN; Davydovskaia MF; Zolotova SN; Lash NIu; Popova NF; Khachanova NV; Shur SG; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7 Suppl 2):107-13. PubMed ID: 19891354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A changing treatment landscape for multiple sclerosis: challenges and opportunities.
    Piehl F
    J Intern Med; 2014 Apr; 275(4):364-81. PubMed ID: 24444084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MS pipeline flowing, but niche remains for neuroprotection.
    Waters H
    Nat Med; 2011 Nov; 17(11):1327. PubMed ID: 22064394
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term follow-up of clinical trials of multiple sclerosis therapies.
    Freedman MS
    Neurology; 2011 Jan; 76(1 Suppl 1):S26-34. PubMed ID: 21205679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.